Aerie Pharmaceuticals Logo

Our VISIONaerie® Legacy

Our Journey to Transform Glaucoma Treatment

Our VISIONaerie® co-founder, David L. Epstein, M.D. (1943-2014), began Aerie with a spirit of intellectual curiosity and commitment to discovery that remains with us today.

“Targeting the diseased tissue to restore normal function is a fundamental tenet of medicine, yet no available glaucoma therapies do this. We founded Aerie with the specific goal of bringing a safe and effective trabecular outflow drug to physicians and their patients.” - David Epstein, M.D., former Duke University Chairman of the Department of Ophthalmology and Aerie Co-founder1

Dr. Epstein began Aerie along with his co-founders Eric Toone, Ph.D., and Casey C. Kopczynski, Ph.D. in a quest to discover a glaucoma treatment that improved trabecular outflow. The initial phases of research were filled with twists and turns, but the team was committed to the mission and to letting the data guide them.

“Innovation is rarely a linear process, especially in drug development. In a startup, you have to be focused, but more importantly you have to follow the data, even if it takes you in a different direction than originally planned.” - Casey Kopczynski, Ph.D., Aerie Co-founder1

Dr. Epstein’s legacy has created a strong bond between Aerie and the eye care community, and continues to inspire the company’s commitment to addressing the unmet needs of patients. His spirit of intellectual curiosity, innovation, and commitment to patients remains with us today. It’s part of everything we do. We’re proud of the journey we’ve been on, and we’re excited about where we’re going.

1. Serle JB, Kopczynski CC. The quest for a trabecular outflow drug. Ophthalmology Times. 2014:12-13. Accessed February 8, 2017.